Dr. Ailawadhi on Next Steps With Lisaftoclax in CLL

Video

In Partnership With:

Sikander Ailawadhi, MD, discusses the next steps with lisaftoclax in chronic lymphocytic leukemia.

Sikander Ailawadhi, MD, consultant, Division of Hematology/Oncology, Department of Internal Medicine, professor of medicine, Division of Hematology/Oncology, Departments of Medicine and Cancer Biology, Mayo Clinic, discusses the next steps with lisaftoclax in chronic lymphocytic leukemia (CLL).

During the 2021 ASCO Annual Meeting, findings from a phase 1 study demonstrated encouraging activity with the novel BCL-2 inhibitor lisaftoclax in patients with relapsed/refractory CLL and small lymphocytic lymphoma.

The study is ongoing, says Ailawadhi. The recommended phase 2 dose of 600 mg of lisaftoclax is being evaluated in patients with a high risk of developing tumor lysis syndrome (TLS), Ailawadhi says. Additionally, the final patient with a low risk of developing TLS has consented to treatment with lisaftoclax, so if the safety data prove favorable, the phase 2 expansion study will likely commence in that patient cohort, Ailawadhi explains.  

Notably, 3 ongoing studies evaluating lisaftoclax are ongoing in CLL, multiple myeloma, and Waldenström macroglobulinemia, concludes Ailawadhi.

Related Videos
Petros Grivas, MD, PhD, professor, Clinical Research Division, Fred Hutchinson Cancer Center; professor, Division of Hematology and Oncology, University of Washington (UW) School of Medicine; clinical director, Genitourinary Cancers Program, UW Medicine
Somedeb Ball, MBBS, assistant professor, medicine, Division of Hematology Oncology, Department of Medicine, Vanderbilt University Medical Center
Phillip J. Koo, MD
Gabriella Smith, MD
Mikkael A. Sekeres, MD, MS
Francesco Di Meo, PhD
Ko Un “Clara” Park, MD
Naseema Gangat, MBBS
Erin Frances Cobain, MD
Pashtoon Murtaza Kasi, MD, MS